Enveda to present late-breaker oral data on ENV-294 at EADV 2026

Enveda said new mechanistic and biomarker data from the Phase 1b trial of ENV-294 in moderate-to-severe atopic dermatitis were accepted for a late-breaking oral presentation at the EADV 2026 Congress in Vienna.